Vision Loss Clinical Trials

A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 69 clinical trials
A Prospective Randomized Double-Blind Placebo-Controlled Crossover Study to Evaluate the Clinical Utility of the Vascular Health Profile Diagnostics Assay (VHP) in Assessment of Response to Administration of a HMG-CoA reductase inhibitor (statin) as Primary Prevention in Patients with Asymptomatic Atherosclerosis

This is a prospective, single-center, randomized double-blind, placebo-controlled, crossover study conducted in the United States (US). Patients will be randomized into two treatment sequences (treatment A in period 1, followed by treatment B in period 2, or treatment B in period 1, followed by treatment A in period 2).

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 2 Multi-center Randomized Double-Blind Placebo-Controlled Dose Range Finding Study to Evaluate the Safety Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects who have Diabetic Foot Ulcer with Peripheral Arterial Disease

This is a Phase 2, randomized, double-blind, placebo-controlled, dose range finding study in subjects who have DFU with PAD. The study will enroll approximately 24 subjects.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A randomized double-blind placebo controlled multi-center study to assess the effect of ranolazine on outcomes in subjects with pulmonary hypertension and right ventricular dysfunction accompanied by a comparative study of cellular metabolism in subjects with pulmonary hypertension with and without right ventricular dysfunction

A multi-center study evaluating the effects of ranolazine in subjects with class II/III/IV pulmonary hypertension on stable background therapy and persistent RV dysfunction. Study involves an observational arm and a 26-week treatment arm. At baseline (wk 0), interim (wk 13) and the conclusion of treatment period (wk 26) subjects will …

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure with Preserved Ejection Fraction

The purpose of this study is to test the effect of prolonged therapy (24 weeks) with isosorbide dinitrate ± hydralazine on arterial wave reflections, exercise capacity, left ventricular (LV) mass/fibrosis and diastolic function in patients with Heart Failure and Preserved Ejection Fraction (HFPEF). This is a double-blind, placebo-controlled pilot randomized …

  • 0 views
  • 19 Feb, 2024
  • 1 location
A multicentre multinational randomised parallel-group placebo-controlled (double blind) and active-controlled (open) trial to compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily Norditropin FlexPro in adults with growth hormone deficiency for 35 weeks with a 53-week extension period (PRIME)

The trial will compare the efficacy and safety of once weekly dosing of NNC0195-0092 with once weekly dosing of placebo and daily dosing of Norditropin® in adult subjects with growth hormone deficiency.

  • 0 views
  • 19 Feb, 2024
  • 1 location
18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimers Disease

BAN2401-G000-301 (Study 301) is an 18-month treatment (Core Study), multicenter, double-blind, placebo-controlled, parallel-group study in subjects with EAD (mild cognitive impairment [MCI] due to AD with intermediate likelihood/Prodromal AD or mild AD dementia) with confirmed amyloid pathology indicated by either positive amyloid load confirmed by amyloid PET assessment or CSF …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction

., galantamine (GAL)] may suppress inflammation and reverse or prevent neurocognitive deficits in HIV-1 infection. In this double-blind, placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers, 60 nonsmokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Padsevonil as adjunctive treatment of focal-onset seizures

You are being asked to participate in this clinical research study because you have epilepsy associated with focal onset seizures (or sometimes called partial seizures), and your seizures are not well controlled with your current treatment. Seizures are caused by abnormal electrical disturbances in the brain. Focalonset seizures occur when …

  • 0 views
  • 19 Feb, 2024
  • 1 location